BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 221 filers reported holding BRIDGEBIO PHARMA INC in Q1 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $24,753,519 | +106.7% | 938,700 | +34.9% | 0.02% | +110.0% |
| Q2 2023 | $11,972,782 | -2.4% | 696,092 | -5.9% | 0.01% | -9.1% |
| Q1 2023 | $12,269,067 | +76.3% | 739,992 | -19.0% | 0.01% | +83.3% |
| Q4 2022 | $6,959,285 | -32.5% | 913,292 | -12.0% | 0.01% | -40.0% |
| Q3 2022 | $10,315,000 | +7.9% | 1,037,730 | -1.4% | 0.01% | +11.1% |
| Q2 2022 | $9,560,000 | -16.8% | 1,052,830 | -7.0% | 0.01% | 0.0% |
| Q1 2022 | $11,493,000 | -34.4% | 1,132,350 | +7.8% | 0.01% | -25.0% |
| Q4 2021 | $17,526,000 | -18.9% | 1,050,740 | +128.0% | 0.01% | -20.0% |
| Q3 2021 | $21,601,000 | -20.7% | 460,860 | +3.1% | 0.02% | -16.7% |
| Q2 2021 | $27,241,000 | +24.5% | 446,860 | +25.8% | 0.02% | +20.0% |
| Q1 2021 | $21,883,000 | – | 355,237 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |